ImmunoVaccine Inc. Share Price Toronto S.E.
Equities
IMV
CA45254B1031
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
|
2023 | Transcript : IMV Inc., Q4 2022 Earnings Call, Mar 16, 2023 | |
2022 | Transcript : IMV Inc., Q3 2022 Earnings Call, Nov 11, 2022 |
Sales 2021 | - | Sales 2022 | - | Capitalization | 3.06Cr 4.17Cr 255.47Cr |
---|---|---|---|---|---|
Net income 2021 | -3.6Cr -4.91Cr -300.53Cr | Net income 2022 | -3.8Cr -5.18Cr -317.22Cr | EV / Sales 2021 | - |
Net cash position 2021 | 1.9Cr 2.59Cr 158.29Cr | Net Debt 2022 | 76.74L 1.05Cr 64Cr | EV / Sales 2022 | - |
P/E ratio 2021 |
-2.47
x | P/E ratio 2022 |
-0.53
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.93% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Hall
CEO | Chief Executive Officer | - | 10/20/10 |
Brittany Davison
DFI | Director of Finance/CFO | - | - |
Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 58 | 01/20/01 | |
Kyle Kuvalanka
BRD | Director/Board Member | 56 | 01/21/01 |
Markus Warmuth
BRD | Director/Board Member | 53 | 06/18/06 |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 4.53TCr | |
+41.98% | 4.04TCr | |
-10.06% | 3.79TCr | |
+31.15% | 3.18TCr | |
-7.79% | 2.77TCr | |
+13.32% | 2.65TCr | |
+43.05% | 1.4TCr | |
+31.28% | 1.24TCr | |
-7.41% | 1.13TCr |
- Stock Market
- Equities
- IMVIF Stock
- IMV Stock